Mylan, Ranbaxy Push 3rd Circ. To Nix Provigil Class
Mylan and Ranbaxy said Thursday that purchasers bringing pay-for-delay claims over the narcolepsy drug Provigil have failed to give the Third Circuit any good reason to uphold a class certification order,...To view the full article, register now.
Already a subscriber? Click here to view full article